Initial Recurrence of Glioblastoma Multiforme

A PHASE 2 STUDY OF MEDI-575 IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA (IIRB #24347)

Initial Recurrence of Glioblastoma Multiforme

  • Histologically confirmed diagnosis of World Health Organiazation Grade IV malignant glioma (glioblastoma or gliosarcoma)
  • Documented first recurrence of GBM by diagnostic biopsy or by contrast-enhanced MRI

The purpose of this trial is to evaluate the progression-free survival at 6 months in adult subjects with a first recurrence of Glioblastoma Multiforme (Stage IV malignant glioma) following first-line therapy of temozolomide and radiation who are treated with MEDI-575.  This is a Phase 2, multicenter, open-label, single-arm study that consists of an IV infusion every 21 days.

MEDI-575 is a fully human immunoglobulin monoclonal antibody to PDGFRα (platelet-derived growth factor receptor alpha).  The PDGFRα pathway, with its potential role in regulating transformation, tumor microenvironment, progression, and metastasis, may be an important cancer target.  MEDI-575 inhibits signaling from PDGRFα on cancer cells and cancer-associated fibroblasts.

Surasak Phuphanich, MD, FAAN
Director, Neuro-oncology Program
phuphanich@cshs.orG
Phone: (310) 423-8100

Christy Davis, RN
christy.davis2@cshs.org
Phone: (310) 423-0022

print button
WP2